Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;39(4):1039-1047.
doi: 10.1007/s10067-020-04963-2. Epub 2020 Feb 3.

Obesity and its role in the management of rheumatoid and psoriatic arthritis

Luca Moroni  1   2 , Nicola Farina  3   4 , Lorenzo Dagna  3   4
Affiliations
Review

Obesity and its role in the management of rheumatoid and psoriatic arthritis

Luca Moroni et al. Clin Rheumatol. 2020 Apr.

Abstract

In the last decade, interest has been growing in the relationship between obesity and several other clinical conditions, besides the well-established links between body mass index (BMI) and cardiovascular diseases or cancer. A particular focus has been put on the impact of a higher BMI on immune-mediated diseases such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Obesity has been found to be associated with greater arthritis activity and a reduced probability of response to anti-tumor necrosis factor (TNF) agents. On the other hand, weight loss increases the chances of treatment success. Although the direct effect of a higher body mass on drug clearance might in part account for this obesity-related effect, other biological mechanisms could be involved. The evidence of a negative influence of obesity on arthritis treatment is particularly strong as far as anti-TNF inhibition is concerned; on the contrary, the response to biologic agents targeting interleukin-6, cytotoxic T lymphocyte antigen 4, or CD20 seems not to be negatively affected by a higher BMI. In this review, we will consider the main studies investigating the influence of obesity on anti-rheumatic treatment in RA and PsA patients. We will also try to hypothesize about a possible pathogenic explanation of this phenomenon and its role in the choice of an appropriate and personalized therapy.

Keywords: Body mass index; Obesity; Psoriatic arthritis; Rheumatoid arthritis.

PubMed Disclaimer

References

    1. Withrow D, Alter DA (2011) The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev 12(2):131–141. https://doi.org/10.1111/j.1467-789X.2009.00712.x - DOI - PubMed
    1. Liu Y, Hazlewood GS, Kaplan GG, Eksteen B, Barnabe C (2017) Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 69(2):157–165. https://doi.org/10.1002/acr.22932 - DOI
    1. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH, Curtis JR, Furst DE, Parks D, Kavanaugh A, O'Dell J, King C, Leong A, Matteson EL, Schousboe JT, Drevlow B, Ginsberg S, Grober J, St Clair EW, Tindall E, Miller AS, McAlindon T (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheum 68(1):1–26. https://doi.org/10.1002/art.39480 - DOI
    1. Passot C, Mulleman D, Bejan-Angoulvant T, Aubourg A, Willot S, Lecomte T, Picon L, Goupille P, Paintaud G, Ternant D (2016) The underlying inflammatory chronic disease influences infliximab pharmacokinetics. mAbs 8(7):1407–1416. https://doi.org/10.1080/19420862.2016.1216741 - DOI - PubMed - PMC
    1. Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121(6):2111–2117. https://doi.org/10.1172/JCI57132 - DOI - PubMed - PMC

MeSH terms

Substances

LinkOut - more resources